Impaired left-ventricular global longitudinal strain by feature-tracking cardiac MRI predicts mortality in systemic sclerosis

Fehér, Attila; Miller, Edward J.; Peters, Dana C.; Mojibian, Hamid; Sinusas, Albert J.; Hinchcliff, Monique; Baldassarre, Lauren A.

doi:10.1007/s00296-023-05294-6

Cited by 7 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, native T1 mapping and ECV, which provide information about diffuse fibrosis, missed by LGE, can be used to evaluate the early results of various antifibrotic treatments [78]. Additionally, the combination of LV GLS and LGE were found to be predictive of overall survival [79]. Notably, improvements in RV and LV strain also correlated with improvements in clinical outcomes [80].…”

Section: Myocardial Fibrosis Assessmentmentioning

confidence: 99%

Diagnosis and management of primary heart involvement in systemic sclerosis

De Luca,

Matucci-Cerinic,

Mavrogeni

2023

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review In systemic sclerosis (SSc) primary heart involvement (pHI) is frequent, even though often unrecognized due to its occult nature and to the lack of a specific diagnostic algorithm. The purpose of this review is to report the state of the art of the evidence in the current literature, as well as the overall diagnostic modalities and therapeutic strategies for primary heart involvement in SSc. Recent findings SSc-pHI is defined by the presence of cardiac abnormalities that are predominantly attributable to SSc rather than other causes and/or complications; it may be sub-clinical and must be confirmed through diagnostic investigations. Novel electrocardiographic analysis and cardiac magnetic resonance (CMR) with mapping techniques have been recently proposed, showing a great utility in the early identification of SSc-pHI and in the noninvasive characterization of myocardial tissue. Immunosuppressive therapy emerged as fundamental to curb myocardial inflammation, and recent preclinical and clinical data support the role of antifibrotic drugs to treat SSc-pHI. Summary our review will help clinicians to properly integrate the available diagnostic modalities for the assessment of SSc-pHI. The ultimate goal is to propose a feasible diagnostic algorithm for the early identification of patients with SSc-pHI, and a schematic therapeutic approach to manage SSc-pHI.

show abstract

Section: Myocardial Fibrosis Assessmentmentioning

confidence: 99%